Glycomet-GP 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combination of these two agents offers complementary mechanisms of action, facilitating better blood glucose regulation in patients inadequately controlled by diet, exercise, or monotherapy. Glycomet-GP 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to Glimepiride. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Dose adjustments should be individualized based on clinical response and tolerability to optimize therapeutic outcomes.